| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1369117 | Bioorganic & Medicinal Chemistry Letters | 2015 | 5 Pages |
Abstract
Antagonism of the chemokine receptor CXCR2 has been proposed as a strategy for the treatment of inflammatory diseases such as arthritis, chronic obstructive pulmonary disease and asthma. Earlier series of bicyclic CXCR2 antagonists discovered at AstraZeneca were shown to have low solubility and poor oral bioavailability. In this Letter we describe the design, synthesis and characterisation of a new series of monocyclic CXCR2 antagonists with improved solubility and good pharmacokinetic profiles.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Rupert P. Austin, Colin Bennion, Roger V. Bonnert, Lal Cheema, Anthony R. Cook, Rhona J. Cox, Mark R. Ebden, Alasdair Gaw, Ken Grime, Premji Meghani, David Nicholls, Caroline Phillips, Neal Smith, John Steele, Jeffrey P. Stonehouse,